Clinical study of indocyanine green fluorescence imaging in assisting biopsy of musculoskeletal tumor

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200060540

Enrollment

Unknown

Registered

2022-06-04

Start date

2021-10-01

Completion date

Unknown

Last updated

2024-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bone and soft-tissue tumor

Interventions

Experimental group:Indocyanine green for injection

Control group:None

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. The imaging data are considered to be bone and soft tissue tumors, and it is recommended to determine the treatment plan by puncture biopsy; 2. Exclude the contraindications of cardiovascular and cerebrovascular system puncture.

Exclusion criteria

Exclusion criteria: 1. Imaging considered as nonneoplastic lesions; 2. There are signs of fever, elevated inflammatory indexes, and infection; 3. Thyroid autonomic nodule, allergic to iodine or shellfish; 4. Severe chronic kidney, liver, or lung diseases.

Design outcomes

Primary

Measure	Time frame
Biopsy positive rate;	—

Secondary

Measure	Time frame
False positive rate;False negative rate;Bleeding volume;Operation time;Infection rate;	—

Countries

China

Contacts

Public ContactXie Yuanlong

Zhongnan Hospital of Wuhan University

yuanlongxie@whu.edu.cn+86 15527139855

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026